Thursday, April 9, 2009

Johns Hopkins: Read My Lips--No More Gifts!

To a surprising amount of fanfare and press, Johns Hopkins has voted to ban free samples and to restrict some gifts from drug companies. But it is hardly a “ban” on gifts, though you wouldn’t know it from the news reports.

Here’s what has been reported, followed by what the new guidelines actually do.

1. NO MORE FREE DRUG SAMPLES. This is true. Here is the relevant excerpt:

The practice of accepting free pharmaceutical samples risks interference with one’s prescribing practices since industry representatives often provide the newest and most costly drugs. Therefore, free pharmaceutical samples and vouchers for free pharmaceutical samples may not be accepted.

2. NO MORE FREE GIFTS…er, at least no pens, mugs, and notepads, a redundant rule because these were already banned months ago under PhRMA’s updated Code on Interactions with Health Professionals
, eg., the “no tchotchkes rule.” But expensive textbooks, anatomical models, and informational posters are okay. Therefore, while a company cannot simply hand a Hopkins doctor a new i-pod nano, it can save the doctor the $100 he or she would have otherwise spent on a new textbook. Said doctor can then use these savings to buy a fourth generation i-pod nano online for $99.99.

3. NO MORE FREE FOOD…er, except at industry-supported CME events, where you can enjoy a nice meal free of charge as long as you are also getting free CME credit as well. Otherwise, NO FREE MEALS...umm, well, you can have meal if it’s part of an industry sponsored consultation gig…and, let’s see, if it is offered at a professional society meeting… and, oh yeah, if it’s part of a “research meeting”…and if the drug company gave an “unrestricted grant” to the department which decided to use that money for free food, that’s okay, as long as the company HAD NO INPUT INTO WHICH ENTRÉE WAS OFFERED. But if a drug rep invites you out to dinner in order to try to convince you to prescribe more of his drug, you must refuse the invitation…wait a minute…you CAN go out to dinner with him, but you have to pay for your own meal! (He can share an appetizer with you though) (Okay, and you can have a sip of his martini).

4. NO MORE CASH GIFTS. Johns Hopkins will no longer allow drug reps to hand doctors thick wads of money in unmarked envelopes! HOWEVER, (quoting directly from the new policy) “Gifts from industry may be used by the department to support faculty and staff education, research, and/or patient education. Distribution of the funds will be at the discretion of the department director, who will disseminate the criteria for requesting funds to all faculty members in the department.”

Okay, so let me get this straight. Companies are still allowed to give unlimited amounts of cash to academic departments, and the departments can do anything they want with the cash. Now that’s the kind of gift ban any key opinion leader on the gravy train can support!

Oh, and here’s a nice bonus. Drug companies can still give individual doctors thick wads of cash, as long as it is called a “prize” for “scientific or medical achievements.” To quote again from the policy: “For purposes of this policy, prizes and awards are not considered gifts.”

The bottom line is that Johns Hopkins has crafted a policy to generate good PR for the university, but which continues to allow a free flow of money, food, and educational gifts from the pharmaceutical industry to doctors. Let’s hope that our other academic medical centers can do better.

Monday, April 6, 2009

Seroquel XR and Marcia Angell's Blueprint for the FDA

There's a nice editorial by Marcia Angell (former editor of New England Journal of Medicine and author of the classic book The Truth About Drug Companies) in today's Boston Globe.

Dr. Angell lays out seven specific recommendations for changes in FDA policy, all of which are sensible and will encourage better drug pipelines and safer medications.

Before presenting them, I want to highlight her recommendation number 5, which is that the FDA should be able to require drug companies to compare new drugs with existing drugs of the same type. This is especially relevant in the context of an upcoming meeting of the FDA's Psychopharmacological Advisory Committee. Tomorrow it will begin a two day meeting to discuss, among other things, AstraZeneca's application to approve Seroquel XR for generalized anxiety disorder (GAD) and major depression (you can learn the particulars here).

Seroquel XR is, indeed, more effective than placebo for both depression and GAD. Nonetheless, the application should be soundly rejected, unless AZ can show that Seroquel XR works better than the dozens of other drugs that are already available for these conditions. Why approve an antidepressant that causes weight gain, diabetes, and cardiac death, when there are equally effective alternatives that cause none of these side effects?

I doubt that AZ has done such comparative studies, because they were not forced to do so. From their stockholders' perspective, they would be foolish to conduct such studies, because there's a good chance that Seroquel would do no better than drugs like Zoloft or Celexa. Its disadvantageous side effect profile would be highlighted in a head-to-head trial. And as we know from recent court documents, AZ has done everything it can to
bury the truth about Seroquel's side effects.



Marcia Angell's Seven Recommendations for a Better FDA:

1. Congress should repeal the Prescription Drug User Fee Act.


2. Consultants for drug companies should no longer be permitted to serve on FDA advisory panels.


3. The agency should see that the post-marketing studies it mandates are actually carried out.


4. The FDA should review generic drugs as fast as brand-name drugs.


5. Congress should give the FDA the authority to require drug companies to compare new drugs with existing drugs of the same type.


6. The FDA should stop approving me-too drugs on the basis of surrogate endpoints.


7. The FDA should prohibit direct-to-consumer advertising for three years after drugs are approved.


Thursday, April 2, 2009

JAMA Recommendations for Medical Societies and Industry; or, Breaking Up Is Hard To Do

This week, JAMA published a major paper outlining recommendations for what kinds of money professional medical societies should and should not accept from the pharmaceutical industry.

The short version is that the authors believe that PMAs can continue to accept advertising and exhibit booth money, but that all other funding should eventually be eliminated. But they realize that many associations would probably cease to function if they had to divorce their patrons immediately, so they recommend a number of “interim” measures. Below are some of their key recommendations, followed by how the American Psychiatry Association deals with some of these issues.

·PMA leadership. All leaders, elected or non-elected, should have no financial relationships with industry.

APA: New rules now require that anybody involved in any level of governance, including committees, task forces, and councils, must declare their conflicts of interest at the beginning of meetings. While there are no restrictions on conflicts for leadership, most of the current officials (with the conspicuous exception of the president-elect, Dr. Schatzberg) have no relationships with industry. This should become a requirement of election.

·Practice guidelines committees. Typically, such committees are comprised mainly of academics with industry relationships. Furthermore, PMAs often accept industry grants to support the proceedings of such committees and to disseminate the resulting practice guideline materials. The paper recommends no industry involvement of any kind.
APA: Most of the members of APA practice guideline committees have industry relationships, although the organization does not accept industry grants to support the committees. In addition, most of the DSM-V committee members have industry relationships, although they are required to limit such income to no more than $10,000 per year while sitting on the committee. Should we exclude members with industry relationships from participating on any treatment guideline committees or on the DSM committee? The problem with this is that many of the most knowledgeable clinicians do industry-sponsored research and I wouldn’t want to exclude their expertise. Instead, I would propose that we allow a maximum quota of members with industry ties (perhaps no more than 25%), as long as these relationships do not include clear marketing activities, such as promotional speaking, participation in industry-funded CME events, or marketing consultation.

·Product endorsements. The group recommends that PMAs never solicit or accept deals from companies that allow them to offer their services to members.

APA: The APA currently has a number of such relationships, seen as important incentives for psychiatrists to become members of the organization. This includes, most egregiously, an official endorsement of PRMS, a malpractice insurance carrier that accepts money from Eli Lilly to put on pseudo-educational programs. I have written about this topic here. I agree that entering into deals with these companies is fraught with ethical pitfalls, as the PRMS fiasco shows. It’s just not worth it.

·Conference sponsorship. The group would allow industry support of meetings, as long as the money does not influence the content. However, they call for the elimination of industry-supported satellite symposia at meetings.

APA: The APA has just voted to phase out industry support of symposia, and once this is accomplished, there will be no industry support for the annual meeting, other than payments for exhibit booths. I disagree with the report’s willingness to allow even arms-length industry support of educational meetings, which I believe will inevitably lead to promotional activities in the guise of education. Theoretically, setting up “firewalls” between industry money and choice of content is a good idea, but the example of industry-funded CME shows that it is rarely effective in practice.

·Research and fellowships. The group is willing to allow industry grants for research and for fellowships, but they specify that research grants should not be pegged to specific research projects. Furthermore, fellowships should not be named after companies, and the fellows should not be told which company supports their fellowship.

APA: The APA currently accepts industry funding for a variety of research projects and for research or travel fellowships, often awarded to residents in support of travel to the annual meeting. I support the paper’s recommendations, but I think it is naïve to believe that any company would support a fellowship if nobody is allowed to know they supported it. Nor do I believe it would possible to keep such information secret.

Monday, March 30, 2009

Devastating Indictment of Industry-Funded CME Published

Occasionally, a piece of investigative journalism sets into motion processes that strike corrupt business practices at their core. Such an article was published yesterday in the Milwaukee Journal Sentinel, written by John Fauber and Suzanne Rust.

The article is entitled “Drug firms' cash skews doctor classes: Company-funded UW courses often favor medicine, leave out side effects.” It is such a devastating indictment of the corruption inherent in drug company funding of CME that it will become required reading for all those involved in health care policy.

The University of Wisconsin has a huge program of industry funded CME. Why? This is fueled largely by George Mejicano , UW’s associate dean for continuing education. Mejicano, who was profiled by Medical Meetings magazine in 2008,
was the driving force behind winning $12.3 million from Pfizer for a CME program on smoking cessation, $3.5 million of which went to UW. Pfizer, of course, markets Chantix, the new smoking cessation drug which is effective but laden with side effects, such as nausea and insomnia, and, potentially, suicidal ideation. These side effects should not necessarily dissuade doctors from prescribing a drug which may ultimately save many lives, but they should be made aware of these risks.

Unfortunately, Fauber and Rust found that the smoking cessation course produced by UW does not even mention Chantix’s side effects. The reporters asked Dr. Mejicano to comment on this and on the fact that the course did not disclose that clinical trials of Chantix excluded patients with common comorbid conditions, such as mental illness and heart disease. Here’s how he responded: “UW's Mejicano said he did not think the side effects or the people excluded from the clinical trials should have been included in the course. He said such courses are rarely comprehensive and are designed to meet selected learning objectives.”

Indeed—and this is precisely the problem with industry funding of CME. The drug companies, via the proxy of various third parties, set the agenda for medical education. That agenda does not include saying bad things about the funder's product. I commend Mejicano’s honesty for essentially admitting this, thought it was apparently an unwitting confession.

The article goes on to profile other UW CME courses, in each case showing how the content is biased in favor of the supporter’s drug. This rogues' gallery includes a course pushing Boehringer Ingelheim's Mirapex for restless leg syndrome and one hawking Bayer’s Yaz and Pfizer’s Xanax XR for premenstrual dysphoric disorder.

I wonder if the American Medical Association, that great defender of industry sponsorship of CME, will respond to this article. Perhaps they can reference it in their new and embarrassing “fact sheets” on CME, which I reviewed here.

Thursday, March 26, 2009

Tufts Blows It

I like Tufts. I'm a voluntary faculty member there, and recently the university promoted me to associate clinical professor of psychiatry (from "assistant") even though I'm a loose cannon in the world of psychiatry.

But Tufts officials just made a silly mistake when they rescinded an invitation to Paul Thacker, one of Senator Charles Grassley's aides, to speak at a conference on conflicts of interest in medicine and research. See full coverage of this issue in today's Boston Globe.

According to Christine Fennelly, a Tufts spokesperson, the decision to disinvite Thacker was made because Senator Grassley has sent a letter requesting financial disclosures to Dr. Helen Boucher, an infectious disease specialist at Tufts. The Globe article quotes Fennelly thusly:

"Indeed . . . the administration felt it prudent to not engage someone from the Senator's office while we respond to the Senator's inquiry."

I don't know who made this decision, but it is a poor one for many reasons. It sets a tone of antagonism rather than cooperation, of opacity rather than transparency. It also deprives the Tufts community of Thacker's opinions. I've had several conversations with him and have found him to be a fascinating person, extremely knowledgable about the effects of conflicts of interest in medicine and in many other fields, and someone with a strong moral compass. Before working for Grassley, he was an eminent and award-winning investigative journalist--you can read about some of his accomplishments in this Wikipedia entry. Some of you may recall this influential article in Salon.com entitled "A Climate-Controlled White House," in which it was revealed that the Bush administration pressured top federal scientists to toe the party line on global warming (please--let's just call it "climate change," shall we?) That was Paul Thacker's work.

Thus, in this decision, Tufts is doing everything a top academic center should never do. It is limiting academic freedom, it is ignoring a contrarian point of view, it is rejecting a distinguished thinker, and it is alienating a vocal portion of its own academic community.

Hopefully, the officials will change their minds. I'm pretty sure Thacker won't be offended if he is re-invited, even under conditions of public relations duress.

Tuesday, March 24, 2009

The AMA, Ethics, and "404 Not Found"

As I announced last week, the APA (American Psychiatric Association) has voted to phase out pharmaceutical industry funding of CME symposia at its annual meeting. The APA now has bragging rights as the first national medical organization to make this needed reform.

So what's shaking over at the AMA (American Medical Association)? Acting on a tip from Kate Peterson at The Prescription Project's blog, PostScript, I did a little investigating. As some faithful readers may recall, last fall, the AMA's Council on Ethical and Judicial Affairs (CEJA) released a report in which they recommended that doctors and medical institutions "must not accept industry funding to support professional education activities." But when the report was brought before the AMA House of Delegates in November, the representatives of for-profit MECCs (medical education and communication companies) were allowed to speak directly to the committee charged with evaluating the proposal. These MECCs, whose very existence depends on industry funding, were persuasive, and the AMA tabled the proposal (see here for details), asking CEJA to go back to the drawing board.

Since then, some unfortunate things have occurred. First, the excellent CEJA report on industry involvement in medical education has been removed from the AMA website. If you follow the original link, you get an unceremonious "404 Not Found" and "The requested document was not found on this server."

I asked CEJA officials why the document was censored, and received a prompt response from Bette-Jane Crigger, Director of Ethics Policy, that read, in part:

Because the report was referred back and CEJA is continuing its deliberations, the document is not posted to CEJA's Web pages. This is standard practice. The document was available last spring as proposed policy in the Delegates Handbook for the 2008 Annual Meeting of the House of Delegates, not as a CEJA posting per se. So, neither censorship nor anything irregular.

Fair enough. I also asked if I could receive a copy of the report to post on my blog for posterity. The answer was not encouraging:

I rather doubt the Council would favor allowing you to post the prior version of its report, but I will raise the question at our next conference call.

Meanwhile, it appears that the eventual conclusion of the revised ethics report is in little doubt. The AMA has posted a series of "fact sheets" from their National Task Force on CME Provider/Industry Collaboration. There are three in all, plus a "Get the Facts Toolkit." For chuckles and giggles, I suggest you read these documents. They appear to have been written by a pharma-funded public relations firm. Here are some choice excerpts:


The pharmaceutical, biotechnology and medical device industries play a significant role in informing healthcare professionals about the availability, value, and proper use of medications, vaccines, and medical devices.

(Yes, and we call this "advertising").


These industries have adopted voluntary guidelines on interactions with healthcare professionals.

(That's right, with a gun to their heads called the "Physician Payments Sunshine Act").


The company then provides funding in the form of an educational grant to an educational provider, for example a medical school, organization or agency that manages the grant funds and is responsible for ensuring independence from commercial influence. In all cases, the company has no input into the faculty selection or content of the educational activity.

(Except that, if the company is displeased with the faculty or the content, they will choose a different MECC to fund--not that this incentive could possibly lead to any influence over content, of course).


The CME activities that are supported by industry must be unbiased, open to a variety of viewpoints, and must not serve as marketing or promotional vehicles for industry.

(Which is why all industry-funded CME focuses singularly on conditions for which the company markets a product--no "promotion" there).


Ethics are important for the AMA and for all of us. But when ethics comes face to face with $1.2 billion in annual industry funding for CME, we pretty much know how lopsided the battle will be.

Friday, March 20, 2009

The King of Cringe Strikes Again

As I've written on this blog before, Dr. Joseph Biederman is an outstanding scientist but is also the prototypical MGH/Harvard narcissist. I speak from experience, having attended the MGH psychiatry residency from 1992-1995. We all joked about our arrogance and hubris and narcissism. It was almost a badge of honor. When you are at the top-ranked psychiatry department in the nation (as MGH has been every single year from 1995 to 2008, according to U.S. News and World Report) you are entitled to an extra heaping of, umm, positive self-regard, shall we say.

So Biederman's seemingly outrageous comments, as reported in today's New York Times, have to be taken into context.

Here are the comments:

In a contentious Feb. 26 deposition between Dr. Biederman and lawyers for the states, he was asked what rank he held at Harvard. “Full professor,” he answered.
“What’s after that?” asked a lawyer, Fletch Trammell.
“God,” Dr. Biederman responded.
“Did you say God?” Mr. Trammell asked.
“Yeah,” Dr. Biederman said.

If you've tasted MGH culture, you'd find this comment very funny. Biederman was not really saying that he was just below God; instead, he was cracking a joke about academic hierarchy at Harvard, presumably to break the tension at the deposition.

The more damning documents are those implying that Biederman promised Johnson & Johnson officials positive data about their products. I haven't reviewed the published studies in question, but knowing the quality of Biederman's research, I suspect that it is well-done and above board. He may have already seen some preliminary data showing advantages of Risperdal over Zyprexa in pediatric bipolar disorder, or showing that Concerta was unlikely to retard growth. I'd be extremely surprised if he manipulated these studies in some fraudulant way to create the results he promised. That's not the way Biederman rolls.

Call him the King of Cringe. Disagree with his opinions about the prevalence of pediatric bipolar disorder. Call him greedy, even. But scientifically, I continue to respect him and I believe that he ultimately has the best interests of his patients at heart.